Insider Selling: Gilead Sciences, Inc. (GILD) Director Sells 60,000 Shares of Stock
Gilead Sciences, Inc. (NASDAQ:GILD) Director Gayle E. Wilson sold 60,000 shares of the company’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $77.92, for a total value of $4,675,200.00. Following the completion of the sale, the director now directly owns 182,258 shares in the company, valued at $14,201,543.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $80.79 on Wednesday. The company has a quick ratio of 3.48, a current ratio of 3.55 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a 1-year low of $63.76 and a 1-year high of $89.54. The company has a market capitalization of $104,684.40, a price-to-earnings ratio of 9.38, a price-to-earnings-growth ratio of -1.83 and a beta of 1.22.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $5.71 billion. During the same period in the previous year, the company posted $2.70 earnings per share. The company’s revenue for the quarter was down 18.7% compared to the same quarter last year. sell-side analysts anticipate that Gilead Sciences, Inc. will post 6.24 EPS for the current fiscal year.
Several equities research analysts recently weighed in on GILD shares. JPMorgan Chase & Co. set a $85.00 price target on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. BMO Capital Markets reaffirmed a “hold” rating and issued a $82.00 price target on shares of Gilead Sciences in a research note on Friday, October 20th. Citigroup raised Gilead Sciences from a “neutral” rating to a “buy” rating and reduced their price target for the stock from $88.80 to $76.00 in a research note on Tuesday, January 30th. Vetr cut Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 price target on the stock. in a research note on Wednesday, January 17th. Finally, Zacks Investment Research cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $87.04.
Large investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Gilead Sciences by 26.6% during the third quarter. Macquarie Group Ltd. now owns 479,332 shares of the biopharmaceutical company’s stock valued at $38,836,000 after purchasing an additional 100,741 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Finally, Toronto Dominion Bank lifted its holdings in shares of Gilead Sciences by 19.0% during the second quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock valued at $33,445,000 after purchasing an additional 75,364 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2018/02/14/insider-selling-gilead-sciences-inc-gild-director-sells-60000-shares-of-stock.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.